Atrial fibrillation (AFib) and gastric sleeve surgery frequently intersect, as obesity is a well-established risk factor for AF and many patients presenting for bariatric procedures carry a pre-existing cardiac diagnosis. Sleeve gastrectomy — one of the most commonly performed bariatric operations in the UK — can influence heart rhythm both in the short term, through perioperative physiological stress, and in the longer term, through favourable cardiac remodelling associated with sustained weight loss. Understanding how these two conditions interact is essential for patients and clinicians to manage risk, optimise medications, and achieve the best possible outcomes.

Understanding the Link Between AFib and Gastric Sleeve Surgery

Obesity is an independent risk factor for AF, and gastric sleeve surgery may reduce AF burden over time through sustained weight loss, though perioperative cardiac risk must be carefully managed by a multidisciplinary team.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the UK, affecting an estimated 1.4 million people according to the British Heart Foundation. It is characterised by disorganised electrical activity in the atria, leading to an irregular and often rapid heart rate. Obesity is a well-established, independent risk factor for AF, with excess adipose tissue contributing to structural and electrical remodelling of the heart over time.

Gastric sleeve surgery — formally known as sleeve gastrectomy — is one of the most frequently performed bariatric procedures in the UK. It involves removing approximately 75–80% of the stomach, restricting food intake and promoting significant, sustained weight loss. Given that obesity and AF frequently coexist, it is not uncommon for patients presenting for bariatric surgery to have a pre-existing diagnosis of AF, or to develop it in the perioperative period.

Research suggests that sustained weight loss following bariatric surgery may reduce the burden of AF over time. A number of observational studies and registry analyses have demonstrated reductions in AF recurrence, symptom frequency, and the need for rhythm-control interventions in patients who achieve significant weight reduction. However, it is important to note that robust randomised controlled trial evidence in this specific population remains limited. The relationship between gastric sleeve surgery and AF is nuanced — the perioperative period itself carries a degree of cardiac risk that must be carefully managed by a multidisciplinary team.

How Gastric Sleeve Surgery May Affect Heart Rhythm

In the short term, electrolyte disturbances and surgical stress can trigger AF; in the longer term, weight loss promotes favourable cardiac remodelling, including reductions in left atrial size and systemic inflammation.

The mechanisms by which gastric sleeve surgery influences heart rhythm are multifactorial. In the short term, the physiological stress of major surgery, fluid shifts, electrolyte disturbances, and the effects of general anaesthesia can all act as triggers for new-onset or recurrent AF. Hypokalaemia and hypomagnesaemia — which can occur in the early postoperative period due to restricted oral intake, vomiting, fluid shifts, and diuretic use — are particularly relevant, as these electrolyte imbalances lower the threshold for arrhythmia. Close electrolyte monitoring in the early postoperative phase is therefore important, in line with British Obesity and Metabolic Surgery Society (BOMSS) postoperative guidance.

In the longer term, weight loss achieved through sleeve gastrectomy is associated with favourable cardiac remodelling. Reductions in left atrial size, improvements in left ventricular function, and decreases in systemic inflammation have all been documented following significant weight loss in observational studies. These changes are thought to reduce the substrate for AF, potentially lowering the risk of recurrence in patients with established disease.

Additionally, obesity-related conditions that independently contribute to AF — including obstructive sleep apnoea (OSA), hypertension, and type 2 diabetes — often improve substantially following bariatric surgery. Where OSA is identified, optimisation with continuous positive airway pressure (CPAP) therapy before and after surgery may further reduce AF burden. Addressing these comorbidities as part of a comprehensive care plan may contribute to improved arrhythmia outcomes over time. It is important to note, however, that individual responses vary, and not all patients will experience resolution or improvement of their arrhythmia following surgery.

Managing Atrial Fibrillation Before and After Bariatric Surgery

AF should be optimally rate- or rhythm-controlled before surgery, with anticoagulation managed according to CHA₂DS₂-VASc score; DOACs are typically paused preoperatively without bridging, in line with UKCPA and EHRA guidance.

Optimising AF management before gastric sleeve surgery is essential to minimise perioperative risk. Patients should ideally have their heart rate or rhythm well controlled prior to surgery. This typically involves:

• Rate control using beta-blockers (e.g., bisoprolol), rate-limiting calcium channel blockers (e.g., verapamil or diltiazem — noting that diltiazem's licensed indications in AF may vary by formulation; refer to the BNF and individual Summary of Product Characteristics), or digoxin in selected cases

• Rhythm control with antiarrhythmic agents or prior cardioversion where appropriate, in line with NICE NG196

• Anticoagulation to reduce the risk of thromboembolic events, particularly stroke, guided by the patient's CHA₂DS₂-VASc score and bleeding risk (HAS-BLED)

A thorough preoperative cardiac assessment, including an ECG and echocardiogram where indicated, is recommended. Patients on anticoagulation therapy require careful perioperative planning. For those taking direct oral anticoagulants (DOACs), these are typically paused before surgery without bridging anticoagulation, in line with UKCPA and EHRA guidance. Bridging with low-molecular-weight heparin is generally reserved for patients on warfarin who are at high thromboembolic risk, and should only be undertaken following specialist assessment.

Following surgery, close monitoring of heart rhythm and electrolytes is important, particularly in the first few weeks when dietary intake is most restricted. Patients should be encouraged to maintain adequate hydration and adhere to nutritional supplementation regimens, which are standard practice following bariatric procedures. Regular follow-up with both the bariatric team and a cardiologist or GP is advisable to reassess the ongoing need for rate or rhythm control medications as weight loss progresses, since drug requirements may change significantly over time.

Risks and Considerations for AFib Patients Undergoing Gastric Sleeve

AF patients face higher perioperative cardiac risk, and anticoagulation management is complex; altered gastric anatomy post-sleeve gastrectomy can affect DOAC pharmacokinetics, requiring specialist review.

Patients with AF who are considering gastric sleeve surgery face a specific set of risks that require careful preoperative counselling. The overall perioperative risk of major adverse cardiac events is higher in individuals with pre-existing arrhythmias compared to those without cardiac disease. Anaesthetic teams should be made fully aware of the patient's cardiac history, current medications, and any implanted cardiac devices such as pacemakers.

Anticoagulation management is one of the most complex considerations. Many AF patients are prescribed direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban, or warfarin, to reduce stroke risk. These agents must be carefully managed around the time of surgery to balance bleeding risk against thromboembolic risk. As noted above, DOACs are generally paused preoperatively without bridging; warfarin bridging is considered only for high thromboembolic risk patients following specialist review. The decision should be made jointly by the surgical and cardiology teams, taking into account the patient's CHA₂DS₂-VASc and HAS-BLED scores.

There is also an important consideration around postoperative absorption of oral medications. Following sleeve gastrectomy, altered gastric anatomy and accelerated gastric emptying can affect the pharmacokinetics of certain drugs. The evidence base for DOAC absorption after bariatric surgery remains limited, and UK guidance from the Specialist Pharmacy Service (SPS) and BOMSS urges caution, particularly in the early postoperative period. Warfarin, whilst requiring more frequent INR monitoring post-surgery due to changes in dietary vitamin K intake and potential alterations in absorption, has the advantage of being directly monitorable. Patients and clinicians should be aware that modified-release formulations of any medication may have unpredictable absorption following bariatric surgery and should be reviewed in line with BOMSS guidance. Patients should be advised not to alter or stop any cardiac medications without first consulting their GP or cardiologist.

Medications for AFib Following Weight Loss Surgery

Significant weight loss after sleeve gastrectomy can alter drug pharmacokinetics and reduce the clinical need for some AF medications; DOAC absorption evidence post-bariatric surgery remains limited, and specialist assessment is recommended.

The management of AF medications following gastric sleeve surgery requires ongoing review, as significant weight loss can alter both drug pharmacokinetics and the clinical need for certain treatments. Beta-blockers such as bisoprolol, commonly used for rate control, are generally well tolerated post-surgery, though dose adjustments may be needed as cardiovascular risk factors improve.

For patients on anticoagulation, the choice of agent and monitoring requirements may need to be revisited. NICE NG196 recommends DOACs over warfarin for most people with AF; however, after bariatric surgery the evidence base for DOAC absorption and efficacy is limited, and UK guidance from the SPS and BOMSS advises caution:

• DOACs (apixaban, rivaroxaban, edoxaban, dabigatran): Evidence on absorption after sleeve gastrectomy is still accumulating. Dabigatran relies on an acidic gastric environment for absorption and may be less reliable following procedures that alter gastric pH or in patients taking proton pump inhibitors. If DOACs are used post-bariatric surgery, specialist assessment of suitability is recommended; drug-specific level monitoring may be considered where available. Refer to individual Summaries of Product Characteristics (SmPCs) and SPS guidance.

• Warfarin: Requires more frequent INR monitoring post-surgery due to dietary changes and potential alterations in absorption. Whilst more burdensome to manage, it has the advantage of direct, quantifiable monitoring. Patients should be counselled about the impact of dietary changes — particularly altered vitamin K intake — on INR stability.

Antiarrhythmic drugs such as amiodarone or flecainide should be continued as prescribed unless a specialist advises otherwise. Clinicians should be aware of key monitoring requirements: amiodarone requires regular thyroid function and liver function checks, and significantly potentiates warfarin (requiring closer INR monitoring). DOACs may also be subject to interactions via P-glycoprotein and CYP3A4 pathways; refer to the BNF and relevant SmPCs. Modified-release formulations of any cardiac medication should be reviewed post-surgery, as absorption may be unpredictable (BOMSS guidance).

As weight loss progresses and comorbidities such as hypertension and sleep apnoea resolve, some patients may find that their AF burden reduces, potentially allowing for a review of long-term medication needs. Any changes to cardiac medications should always be made under medical supervision. Patients who experience suspected side effects from any medicine should report these via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk or via the Yellow Card app).

Experiencing these side effects? Our pharmacists can help you navigate them →

NHS Guidance and When to Seek Medical Advice

AF patients are not excluded from NHS bariatric surgery but require thorough cardiac assessment; emergency symptoms such as stroke signs or chest pain require an immediate 999 call, while palpitations or dizziness warrant urgent GP or NHS 111 contact.

In the UK, bariatric surgery is commissioned by the NHS in line with NICE CG189 (Obesity: identification, assessment and management) and NHS England commissioning criteria, which recommend consideration of bariatric surgery for adults with a BMI of 35 kg/m² or above with obesity-related comorbidities, or a BMI of 40 kg/m² or above. Patients with AF are not automatically excluded from bariatric surgery, but their cardiac status must be thoroughly assessed as part of the preoperative workup. Referral to a cardiologist prior to surgery is standard practice for patients with a significant cardiac history.

The MHRA and NHS advise that patients on anticoagulants or antiarrhythmic medications should not make any changes to their treatment without professional guidance. Following gastric sleeve surgery, patients should attend all scheduled follow-up appointments and report any new or worsening symptoms promptly.

Patients should call 999 or go to their nearest A&E immediately if they experience:

• Signs of stroke — facial drooping, arm weakness, or speech difficulties (use the FAST acronym: Face, Arms, Speech, Time to call 999)

• Chest pain or severe shortness of breath

• Collapse or loss of consciousness

• Severe or unusual bleeding, which may indicate anticoagulation issues

Patients should seek urgent medical advice (contact their GP, bariatric team, or call NHS 111 if unsure) if they experience:

• Palpitations, a racing or irregular heartbeat

• Dizziness, light-headedness, or fainting

• New or worsening breathlessness

• Unusual bruising

For non-urgent concerns — such as questions about medication absorption, dose adjustments, or routine cardiac monitoring — patients should contact their GP or bariatric follow-up team. The NHS Long Term Plan emphasises integrated care for patients with complex comorbidities, and individuals with both obesity and AF are encouraged to engage with their multidisciplinary care team to optimise outcomes safely and effectively. Suspected side effects from any medicine should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions